Helus Pharma Inc.
For the period ended Mar 31, 2024. Filed Jun 26, 2024.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Jun 26, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.3 · Notes:
Notes:
(1)Certain amounts have been converted from USD to CAD at an exchange rate of 1.35:1.
(2)Such amounts do not reflect the entire anticipated expenditures or budget related to the listed programs. For further information see “Non-Revenue Generating Projects”.
(3)Includes personnel costs, professional services, overhead expenses and general expenses to be incurred by the Company in the normal course of business. In addition, the Company intends to use a portion of these proceeds to continue funding both its Deuterated Psilocybin Analog and Deuterated Dimethyltryptamine programs. The allocation between these programs and specific milestones within the programs have not yet been determined.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.